ASH 2020 | Using MRD to improve patient outcomes
Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses how to use measurable residual disease (MRD) measurement to improve outcomes in patients with hematologic malignancies. In acute lymphoblastic leukemia, emerging data using next-generation sequencing has shown that patients who are MRD-negative at high sensitivity have more positive outcomes compared to those who are MRD-positive. Similar data has been reported in patients with chronic lymphocytic leukemia. Dr Jain also highlights the growing importance of MRD in the multiple myeloma field and the use of circulating tumor DNA in diffuse large b-cell lymphoma as an MRD assessment. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.
Disclosures
Nitin Jain, MD, has received research funding from Pharmacyclics, AbbVie, Genentech, AstraZeneca, BMS, Pfizer, ADC Therapeutics, Incyte, Servier, Cellectis, Adaptive Biotechnologies, Precision Biosciences, Aprea Therapeutics and Fate Therapeutics; and has participated in advisory boards or received honoraria from Pharmacyclics, Janssen, AbbVie, Genentech, AstraZeneca, Adaptive Biotechnologies, Servier, Precision Biosciences, Beigene, TG Therapeutics and ADC Therapeutics.
